Interested in joining one of our studies? Please browse our open studies below.
IRIS Infant RSV Immunity Study
The Infant RSV Immune Study (IRIS) follows babies from birth through early childhood to understand how Respiratory Syncytial Virus (RSV) affects the developing immune system. RSV is the leading cause of infant hospitalization in Canada, it is a common winter virus that infects most babies within their first RSV season, and can cause serious lung infections such as bronchiolitis and pneumonia, especially in babies under six months of age.
You may be eligible to participate if you are planning to give birth at BC Women’s Hospital or a local hospital and your baby is due or was delivered in Apr – Jun or Sept – Nov 2026.
QUEST-ADVANCE
The elimination of cervical cancer has been listed by the World Health Organization as a top health priority and Canada is posed to be one of the first countries to achieve this goal. Ongoing evaluation of the HPV vaccine and dosing schedule is critical to optimizing the vaccine’s cancer-eliminating potential.
Females aged 13-27 and males aged 13-22 are invited to participate in this observational study regardless of whether or not they have received the HPV vaccine. Please email questadvance@bcchr.ubc.ca to learn more.
Pneumococcal-20 Vaccine (PCV20) Study
This study is evaluating how children and youth’s immune systems respond to a new vaccine (PCV20) for pneumococcal disease. The PCV20 vaccine is approved in Canada and is over 90% effective in protecting infants and young children against pneumococcal disease caused by 20 strains of Streptococcus pneumoniae (SP).
One dose of PCV20 will be given to children and youth aged 5 to 17 years who have already received their routine pneumococcal vaccines (in line with Health Canada approved use of this vaccine). The study will compare how well the vaccine works in healthy children and youth, compared to those with underlying medical conditions or are receiving treatments that might affect how their body responds and are at higher risk of pneumococcal disease.
Click learn more below to see if you are eligible to participate.
If you are interested in joining one of our studies or
would like to be added to our contact list, click below.